352 related articles for article (PubMed ID: 16461865)
21. Sustained-release naltrexone for opioid dependence.
Lobmaier P; Kornør H; Kunøe N; Bjørndal A
Cochrane Database Syst Rev; 2008 Apr; (2):CD006140. PubMed ID: 18425938
[TBL] [Abstract][Full Text] [Related]
22. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV
Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259
[TBL] [Abstract][Full Text] [Related]
23. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
Rothman RB; Gorelick DA; Heishman SJ; Eichmiller PR; Hill BH; Norbeck J; Liberto JG
J Subst Abuse Treat; 2000 Apr; 18(3):277-81. PubMed ID: 10742642
[TBL] [Abstract][Full Text] [Related]
24. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
25. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
Syed YY; Keating GM
CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
[TBL] [Abstract][Full Text] [Related]
26. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial.
Jayaram-Lindström N; Hammarberg A; Beck O; Franck J
Am J Psychiatry; 2008 Nov; 165(11):1442-8. PubMed ID: 18765480
[TBL] [Abstract][Full Text] [Related]
27. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
[TBL] [Abstract][Full Text] [Related]
28. A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.
Sullivan MA; Bisaga A; Pavlicova M; Carpenter KM; Choi CJ; Mishlen K; Levin FR; Mariani JJ; Nunes EV
Am J Psychiatry; 2019 Feb; 176(2):129-137. PubMed ID: 30336703
[TBL] [Abstract][Full Text] [Related]
29. Clinical effects beyond cocaine use of sustained-release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a double-blind, placebo-controlled randomized trial.
Blanken P; Nuijten M; van den Brink W; Hendriks VM
Addiction; 2020 May; 115(5):917-923. PubMed ID: 31908066
[TBL] [Abstract][Full Text] [Related]
30. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts.
San L; Pomarol G; Peri JM; Olle JM; Cami J
Br J Addict; 1991 Aug; 86(8):983-90. PubMed ID: 1912753
[TBL] [Abstract][Full Text] [Related]
31. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence.
Ling W; Wesson DR; Charuvastra C; Klett CJ
Arch Gen Psychiatry; 1996 May; 53(5):401-7. PubMed ID: 8624183
[TBL] [Abstract][Full Text] [Related]
32. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.
Ngo HT; Tait RJ; Hulse GK
Arch Gen Psychiatry; 2008 Apr; 65(4):457-65. PubMed ID: 18391134
[TBL] [Abstract][Full Text] [Related]
33. Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence.
Aklin WM; Severtson SG; Umbricht A; Fingerhood M; Bigelow GE; Lejuez CW; Silverman K
J Clin Psychiatry; 2012 Aug; 73(8):e1056-61. PubMed ID: 22967782
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
Garbutt JC; Kranzler HR; O'Malley SS; Gastfriend DR; Pettinati HM; Silverman BL; Loewy JW; Ehrich EW;
JAMA; 2005 Apr; 293(13):1617-25. PubMed ID: 15811981
[TBL] [Abstract][Full Text] [Related]
35. Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency.
Epstein DH; Schmittner J; Umbricht A; Schroeder JR; Moolchan ET; Preston KL
Drug Alcohol Depend; 2009 Apr; 101(1-2):92-100. PubMed ID: 19101098
[TBL] [Abstract][Full Text] [Related]
36. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
Kunøe N; Opheim A; Solli KK; Gaulen Z; Sharma-Haase K; Latif ZE; Tanum L
BMC Pharmacol Toxicol; 2016 Apr; 17(1):18. PubMed ID: 27121539
[TBL] [Abstract][Full Text] [Related]
37. Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial.
Ware OD; Sweeney MM; Cunningham C; Umbricht A; Stitzer M; Dunn KE
JAMA Netw Open; 2023 Mar; 6(3):e232278. PubMed ID: 36920397
[TBL] [Abstract][Full Text] [Related]
38. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.
Schottenfeld RS; Chawarski MC; Mazlan M
Lancet; 2008 Jun; 371(9631):2192-200. PubMed ID: 18586174
[TBL] [Abstract][Full Text] [Related]
39. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial.
Nuijten M; Blanken P; van de Wetering B; Nuijen B; van den Brink W; Hendriks VM
Lancet; 2016 May; 387(10034):2226-34. PubMed ID: 27015909
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence.
Xuyi W; Juelu W; Xiaojun X; Haiyan L; Zheyuan L; Zhehui G; Guoming D; Gang L; Jin L; Wei H
Am J Addict; 2014; 23(2):162-9. PubMed ID: 24107112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
